Eagle Pharmaceuticals (EGRX) Misses Q1 EPS by 9c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.38, $0.09 worse than the analyst estimate of $1.47. Revenue for the quarter came in at $36.3 million versus the consensus estimate of $3.41 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• DA Davidson Assumes Knife River Corp. (KNF) at Buy
• JPMorgan Reiterates Overweight Rating on Phibro Animal Health Corp. (PAHC) Ahead of Q4 Print
• Raymond James upgrades AMD, sees $201 billion server CPU market by 2030